Pro Share Advisors LLC Outlook Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $1,293 - $3,880	5,880 Added 29.18%	26,030 $10,000
Q3 2023 Nov 13, 2023	SELL	$0.2 - $1.78 $4 - $42	-24 Reduced 0.12%	20,150 $4,000
Q2 2023 Aug 10, 2023	BUY	$1.02 - $1.89 $2,011 - $3,727	1,972 Added 10.83%	20,174 $35,000
Q1 2023 May 11, 2023	BUY	$1.0 - $1.35 $2,960 - $3,996	2,960 Added 19.42%	18,202 $19,000
Q4 2022 Feb 02, 2023	BUY	$0.87 - $1.33 $1,900 - $2,906	2,185 Added 16.73%	15,242 $16,000
Q3 2022 Nov 04, 2022	SELL	$1.02 - $1.26 $255 - $315	-250 Reduced 1.88%	13,057 $16,000
Q2 2022 Aug 01, 2022	SELL	$0.91 - $2.01 $7,324 - $16,178	-8,049 Reduced 37.69%	13,307 $13,000
Q1 2022 May 10, 2022	BUY	$1.22 - $2.03 $2,311 - $3,846	1,895 Added 9.74%	21,356 $38,000
Q4 2021 Feb 08, 2022	BUY	$1.27 - $2.23 $10,223 - $17,951	8,050 Added 70.55%	19,461 $26,000
Q3 2021 Nov 12, 2021	SELL	$2.12 - $2.76 $23,972 - $31,210	-11,308 Reduced 49.77%	11,411 $25,000
Q2 2021 Aug 13, 2021	BUY	$1.78 - $2.76 $40,439 - $62,704	22,719 New	22,719 $57,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.